Roche enters $1.15 billion licensing deal for Sarepta gene therapy

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's gene therapy for Duchenne muscular dystrophy (DMD) outside the United States, it said on Monday.

from Reuters: Health News https://ift.tt/34KRfiF
via IFTTT